In a move to combat treatment delay, as well as to meet the demand for antibody drugs, the U.S has approved Regeneron Pharmaceutical’s lower dose COVID-19 antibody cocktail that can be administered through injection. The therapy, REGEN-COV, is now permitted to administer casirivimab and imdevimab with a lowered dosage amount of 1200 mg through injection under the skin. Aiming to mimic the natural antibodies the body produces to fight off COVID-19, Regeneron hopes for full approval of REGEN-COV in non-hospitalized patients later in 2021, and expects to deliver one million doses to the US Government in the second quarter. Regeneron is working on adopting the cocktail as a preventative medication as well.
Read more here.
More on: News Regulatory